RESUMEN
Research needs innovative ideas, time for design, performance and discussion of projects, and freedom in the daily routine. Integrating the individual working concepts in the given profile of the university hospital and the national research system requires a suitable institutional framework and individual academic mentoring. German university medicine is shaped by a steep hierarchy and high economic pressure - factors that are justified by the medical care system, but which are counterproductive in research. There is a lack of scientific education, time, incentives, and adequate infrastructure - conditions which do not motivate for a scientific career. The increasing interdisciplinary cooperation between medicine and natural sciences, however, has had a positive impact on medical research. Wissenschaftsrat (German Council of Science and Humanities) and DFG (German Research Foundation) analyzed German university medicine and published forward-looking recommendations, which emphasize that university hospitals have to be structurally adjusted to satisfy the needs of medical research and education. Only after the implementation of the recommendations can it be assessed whether the proposed changes solve the designated problems.
Asunto(s)
Selección de Profesión , Conducta Cooperativa , Educación Médica/organización & administración , Hospitales Universitarios/organización & administración , Relaciones Interinstitucionales , Motivación , Investigación/educación , Facultades de Medicina/organización & administración , Movilidad Laboral , Curriculum/tendencias , Educación de Postgrado en Medicina/organización & administración , Femenino , Predicción , Alemania , Necesidades y Demandas de Servicios de Salud/tendencias , Humanos , Masculino , Médicos Mujeres , Investigación/organización & administraciónAsunto(s)
Transportadoras de Casetes de Unión a ATP/genética , Mutación/genética , Enfermedad de Tangier/genética , Transportador 1 de Casete de Unión a ATP , Colesterol/metabolismo , Análisis Mutacional de ADN/métodos , Humanos , Masculino , Persona de Mediana Edad , Nervio Sural/metabolismo , Nervio Sural/patología , Enfermedad de Tangier/patologíaRESUMEN
Noninvasive tools to quantitate transgene expression directly are a prerequisite for clinical gene therapy. We established a method to determine location, magnitude, and duration of low-density lipoprotein (LDL) receptor (LDLR) transgene expression after adenoviral gene transfer into LDLR-deficient Watanabe hypercholesterolemic rabbits by following tissue uptake of intravenously injected (111)In-labeled LDL using a scintillation camera. Liver-specific tracer uptake was calculated by normalizing the counts measured over the liver to counts measured over the heart that represent the circulating blood pool of the tracer (liver/heart (L/H) ratio). Our results indicate that the optimal time point for transgene imaging is 4 h after the tracer injection. Compared with control virus-injected rabbits, animals treated with the LDLR-expressing adenovirus showed seven-fold higher L/H ratios on day 6 after gene transfer, and had still 4.5-fold higher L/H ratios on day 30. This imaging method might be a useful strategy to obtain reliable data on functional transgene expression in clinical gene therapy trials of familial hypercholesterolemia.
Asunto(s)
Terapia Genética/métodos , Hiperlipoproteinemias/terapia , Radioisótopos de Indio , Lipoproteínas LDL/administración & dosificación , Hígado/metabolismo , Receptores de LDL/genética , Adenoviridae/genética , Animales , Femenino , Expresión Génica , Vectores Genéticos/administración & dosificación , Hiperlipoproteinemias/metabolismo , Inyecciones Intravenosas , Lipoproteínas LDL/farmacocinética , Hígado/diagnóstico por imagen , Conejos , Cintigrafía , Receptores de LDL/metabolismo , Transducción Genética/métodos , Transgenes , Resultado del TratamientoRESUMEN
This study evaluated the sensitivity and specificity of the cerebrospinal fluid (CSF) levels of tau-protein, amyloid-beta-peptide 1-42 (Abeta1-42), ApoE-genotype and the degree of cognitive decline as diagnostic markers for Alzheimer's disease (AD). Data was obtained from 105 AD patients and 68 controls. Median CSF-tau levels were increased (512 pg/ml vs. 145 pg/ml, p<0.001) and Abeta1-42-levels were decreased (238.5 pg/ml vs. 310 pg/ml, p<0.001) in AD patients compared to controls. A weak correlation was found between CSF-Abeta1-42 and MMSE score (r=.245). Within all subjects, a correlation of CSF-Abeta1-42 (r=-.337) and CSF-tau (r=.384) with age was found. The combination of CSF-tau levels and MMSE revealed the highest sensitivity (92%) and specificity (87%). In summary, CSF-tau was a useful biological marker to discriminate AD from normal aging, neurological and psychiatric disorders. CSF-Abeta1-42 showed no additional benefit in discriminating patients from controls but might be useful for tracking the severity of the disease.
Asunto(s)
Enfermedad de Alzheimer/diagnóstico , Péptidos beta-Amiloides/líquido cefalorraquídeo , Apolipoproteínas E/genética , Fragmentos de Péptidos/líquido cefalorraquídeo , Proteínas tau/líquido cefalorraquídeo , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/líquido cefalorraquídeo , Enfermedad de Alzheimer/genética , Biomarcadores/líquido cefalorraquídeo , Estudios de Casos y Controles , Trastornos del Conocimiento/diagnóstico , Diagnóstico Diferencial , Femenino , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Escalas de Valoración PsiquiátricaRESUMEN
UNLABELLED: The introduction of HIV-1 protease inhibitor therapy has significantly improved the expectancy and quality of life for HIV-infected patients. Recent reports have highlighted the development of metabolic complications in patients taking protease inhibitors, including abnormalities in glucose metabolism such as impaired glucose tolerance and type 2 diabetes. The mechanisms by which protease inhibitors induce these metabolic syndromes are not well understood. The aim of this study was to determine whether treatment with the HIV-1 protease inhibitor, saquinavir, influences the early insulin signaling cascade in insulin-sensitive cell lines. METHODS: Insulin-stimulated phosphorylation of insulin receptor (IR-beta), insulin receptor substrates (IRS-1 and IRS-2), association of phosphatidylinositol 3-kinase (PI 3-kinase), Ser 473-phosphorylation of Akt and Thr202/Tyr204-phosphorylated p44/42 MAP kinase in 3T3L1 adipocytes and FAO hepatoma cells incubated with increasing concentrations of saquinavir for 24, 36 hours, 2, 3 and 6 days were measured. Results. Phosphorylation of IR-beta, IRS-1 and IRS-2 was not permanently affected by incubation with therapeutic doses (2.5 microM) of saquinavir for 36 hours. After 24 hours we observed an increase of IR-beta and IRS-1 phosphorylation. However, this initial stimulation of IR-beta and IRS-1 phosphorylation was not permanent and did not result in an increased PI 3-kinase association. Phosphorylation of IRS-2 and MAP kinase as well as glucose transport activity was not altered by therapeutic doses. Doses of 10, 25 and 50 microM of saquinavir altered the early insulin signaling events in a dose-dependent manner. However, this effect was primarily due to the cytotoxic effect of higher saquinavir doses. Glucose transport activity was not significantly reduced in 3T3L1 cells treated with 2.5 microM saquinavir in comparison to the control cells stimulated with insulin. CONCLUSION: Early insulin signaling cascade, essential for normal glucose metabolism, is not affected by therapeutic doses of saquinavir. The reduction of insulin-induced phosphorylation in higher concentrations is primarily related to cytotoxic effects. Other mechanisms than early insulin signaling must be primarily responsible for the metabolic alterations during saquinavir therapy.
Asunto(s)
Inhibidores de la Proteasa del VIH/administración & dosificación , Insulina/metabolismo , Saquinavir/administración & dosificación , Transducción de Señal/efectos de los fármacos , Células 3T3 , Animales , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Insulina/farmacología , Proteínas Sustrato del Receptor de Insulina , Ratones , Proteínas de Transporte de Monosacáridos/metabolismo , Concentración Osmolar , Fosfoproteínas/metabolismo , Fosforilación/efectos de los fármacos , Ratas , Receptor de Insulina/metabolismoRESUMEN
The sites and mechanisms of the catabolism of atherogenic lipoprotein(a) (Lp(a)) are not well understood. Lp(a) is increased in patients with end-stage renal disease, suggesting a renal catabolism of Lp(a). To gain a better insight into renal handling of Lp(a), we established a heterologous rat model to study the renal catabolism of human Lp(a). Pure human Lp(a) was injected into Wistar rats, and animals were sacrificed at different time points (30 minutes to 24 hours). Intact Lp(a) was cleared from the circulation of injected rats with a half-life time of 14.5 hours. Strong intracellular immunostaining for apolipoprotein(a) (apo(a)) was observed in the cytoplasm of proximal tubular cells after 4, 8, and 24 hours. Apolipoprotein B (apoB) was colocalized with glomerular apo(a) 1 to 8 hours after Lp(a) injection, but renal capillaries and tubules remained negative. No relevant amounts of apo(a) fragments were found in the plasma of rats after injection of Lp(a). During all urine collection periods, apo(a) fragments with molecular weights of 50 to 160 kd were detected in the urine, however. Our results show that human Lp(a) injected into rats accumulates intracellularly in the rat kidney, and apo(a) fragments are excreted in the urine. The kidney apparently plays a major role in fragmentation of Lp(a). Despite the fact that rodents lack endogenous Lp(a), rats injected with human Lp(a) may provide a useful heterologous animal model to study the renal metabolism of Lp(a) further.
Asunto(s)
Riñón/metabolismo , Lipoproteína(a)/metabolismo , Fragmentos de Péptidos/metabolismo , Animales , Apolipoproteínas/administración & dosificación , Apolipoproteínas/metabolismo , Apolipoproteínas B/metabolismo , Apoproteína(a) , Semivida , Humanos , Lipoproteína(a)/administración & dosificación , Masculino , Modelos Animales , Ratas , Ratas WistarRESUMEN
We have recently described a novel recycling pathway of triglyceride-rich lipoprotein (TRL)-associated apolipoprotein (apo) E in human hepatoma cells. We now demonstrate that not only TRL-derived apoE but also lipoprotein lipase (LPL) is efficiently recycled in vitro and in vivo. Similar recycling kinetics of apoE and LPL in normal and low density lipoprotein receptor-negative human fibroblasts also indicate that the low density lipoprotein receptor-related protein seems to be involved. Intracellular sorting mechanisms are responsible for reduced lysosomal degradation of both ligands after receptor-mediated internalization. Immediately after internalization in rat liver, TRLs are disintegrated, and apoE and LPL are found in endosomal compartments, whereas TRL-derived phospholipids accumulate in the perinuclear region of hepatocytes. Subsequently, substantial amounts of both proteins can be found in purified recycling endosomes, indicating a potential resecretion of these TRL components. Pulse-chase experiments of perfused rat livers with radiolabeled TRLs demonstrated a serum-induced release of internalized apoE and LPL into the perfusate. Analysis of the secreted proteins identified approximately 80% of the recycled TRL-derived proteins in the high density lipoprotein fractions. These results provide the first evidence that recycling of TRL-derived apoE and LPL could play an important role in the modulation of lipoproteins in vivo.
Asunto(s)
Apolipoproteínas E/metabolismo , Endosomas/metabolismo , Lipoproteína Lipasa/metabolismo , Animales , Línea Celular , Fibroblastos/metabolismo , Humanos , Hiperlipoproteinemia Tipo II/metabolismo , Lipoproteínas HDL/metabolismo , Proteína 1 Relacionada con Receptor de Lipoproteína de Baja Densidad/fisiología , Masculino , Ratas , Ratas Sprague-Dawley , Receptores de LDL/metabolismoRESUMEN
Polymorphisms in a number of candidate genes have been reported to be associated with obesity. We have determined the incidence of the following polymorphisms in the following candidate genes in a group of 388 morbid obese patients (mean body mass index (BMI) 52+/-8.01) who underwent gastric banding surgery: lipoprotein lipase (LpL) t-93 g and N291S; peroxisome proliferator receptor gamma (PPARgamma), P12A, P115Q and c1431t; peroxisome proliferator receptor alpha (PPARalpha) L162V; beta-adrenergic receptor 2 (beta-AR 2), Q27E; beta-adrenergic receptor 3 (beta-AR 3) W64R; uncoupling protein 1 (ucp-1), a-3826g, ucp-2, 45 bp insertion. Only for the ucp2 polymorphism did we find a statistically significant association with obesity. The beta-AR 3 W64R and ucp-1 a-3826g polymorphisms influenced the rate of the development of obesity and may act synergistically.
Asunto(s)
Peso Corporal/genética , Proteínas Portadoras/genética , Proteínas de Transporte de Membrana , Proteínas Mitocondriales , Obesidad Mórbida/genética , Polimorfismo Genético , Adulto , Índice de Masa Corporal , Femenino , Humanos , Canales Iónicos , Masculino , Proteínas , Proteína Desacopladora 2RESUMEN
Lipoprotein metabolism in brain has not yet been fully elucidated, although there are a few reports concerning lipids in the brain and lipoproteins and apolipoproteins in the cerebrospinal fluid (CSF). To establish normal levels of lipoproteins in human CSF, total cholesterol, phospholipids, and fatty acids as well as apolipoprotein E (apoE) and apoA-I levels were determined in CSF samples from 216 individuals. For particle characterization, lipoproteins from human CSF were isolated by affinity chromatography and analyzed for size, lipid and apolipoprotein composition. Two consecutive immunoaffinity columns with antibodies, first against apoE and subsequently against apoA-I, were used to define four distinct lipoprotein classes. The major lipoprotein fraction consisted of particles of 13;-20 nm containing apoE and apoA-I as well as apoA-IV, apoD, apoH, and apoJ. In the second particle class (13;-18 nm) mainly apoA-I and apoA-II but no apoE was detected. Third, there was a small number of large particles (18;-22 nm) containing no apoA-I but apoE associated with apoA-IV, apoD, and apoJ. In the unbound fraction we detected small particles (10;-12 nm) with low lipid content containing apoA-IV, apoD, apoH, and apoJ. In summary, we established lipid and apolipoprotein levels in CSF in a large group of individuals and described four distinct lipoprotein classes in human CSF, differing in their apolipoprotein pattern, lipid composition, and size. On the basis of our own data and previous findings from other groups, we propose a classification of CSF lipoproteins.
Asunto(s)
Apolipoproteína A-I/líquido cefalorraquídeo , Apolipoproteínas E/líquido cefalorraquídeo , Lipoproteínas/líquido cefalorraquídeo , Lipoproteínas/aislamiento & purificación , Fosfolípidos/líquido cefalorraquídeo , Western Blotting , Colesterol/líquido cefalorraquídeo , Cromatografía de Afinidad , Cromatografía en Gel , Ácidos Grasos/líquido cefalorraquídeo , Femenino , Humanos , Lipoproteínas/clasificación , Masculino , Microscopía ElectrónicaRESUMEN
Because increased oxidation is an important feature of Alzheimer's disease (AD) and low concentrations of antioxidant vitamins C and E have been observed in cerebrospinal fluid (CSF) of AD patients, supplementation with these antioxidants might delay the development of AD. Major targets for oxidation in brain are lipids and lipoproteins. We studied whether supplementation with antioxidative vitamins E and C can increase their concentrations not only in plasma but also in CSF, and as a consequence decrease the susceptibility of lipoproteins to in vitro oxidation. Two groups, each consisting of 10 patients with AD, were for 1 month supplemented daily with either a combination of 400 IU vitamin E and 1000 mg vitamin C, or 400 IU vitamin E alone. We found that supplementation with vitamin E and C significantly increased the concentrations of both vitamins in plasma and CSF. Importantly, the abnormally low concentrations of vitamin C were returned to normal level following treatment. As a consequence, susceptibility of CSF and plasma lipoproteins to in vitro oxidation was significantly decreased. In contrast, the supplementation with vitamin E alone significantly increased its CSF and plasma concentrations, but was unable to decrease the lipoprotein oxidizability. These findings document a superiority of a combined vitamin E + C supplementation over a vitamin E supplementation alone in AD and provide a biochemical basis for its use.
Asunto(s)
Enfermedad de Alzheimer/sangre , Enfermedad de Alzheimer/tratamiento farmacológico , Antioxidantes/uso terapéutico , Ácido Ascórbico/uso terapéutico , Lipoproteínas/sangre , Vitamina E/uso terapéutico , Edad de Inicio , Anciano , Enfermedad de Alzheimer/líquido cefalorraquídeo , Apolipoproteína A-I/sangre , Apolipoproteínas B/sangre , Apolipoproteínas E/sangre , Apolipoproteínas E/líquido cefalorraquídeo , Ácido Ascórbico/sangre , Ácido Ascórbico/líquido cefalorraquídeo , Colesterol/sangre , Colesterol/líquido cefalorraquídeo , Suplementos Dietéticos , Quimioterapia Combinada , Ácidos Grasos no Esterificados/sangre , Ácidos Grasos no Esterificados/líquido cefalorraquídeo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de Tiempo , Triglicéridos/sangre , Triglicéridos/líquido cefalorraquídeo , Vitamina E/sangre , Vitamina E/líquido cefalorraquídeoRESUMEN
Variation in the peroxisome proliferator-activated receptor gamma (PPAR gamma) gene may play a role in the development of type 2 diabetes mellitus. Therefore we investigated the association between the P12A and c1431t polymorphisms in the PPAR gamma gene and type 2 diabetes. The incidence of the P12A polymorphism was determined by PCR-RFLP and the c1431t by single-strand conformation polymorphism analysis in 219 patients with, and 429 without type 2 diabetes. The frequency of the A allele of P12A polymorphism was 0.16 and the t allele of c1431t polymorphism, 0.13 in patients with type 2 diabetes, and 0.13 and 0.12 respectively in subjects without diabetes 3.2% of patients with and 1.4% without type 2 diabetes were A12A. Since the polymorphisms are not linked the association of the 9 possible genotypes with type 2 diabetes was determined. All patients with genotype A12A/c1431c had type 2 diabetes (n = 3, p = 0.038). There was no association between A12A/t1431t and diabetes. DNA sequencing revealed no additional mutations in the coding region of the PPAR gamma gene in genotypes A12A/c1431c or A12A/t1431t. The associations found between polymorphisms in the PPAR gamma gene and type 2 diabetes suggest that either the A12 isofrom is functional leading to a predisposition to type 2 diabetes in homozygotes or that there is a third, unknown mutation linked to the A12/c1431 haplotype which is responsible.
Asunto(s)
Diabetes Mellitus Tipo 2/genética , Polimorfismo Genético , Receptores Citoplasmáticos y Nucleares/genética , Factores de Transcripción/genética , Adulto , Anciano , Alelos , Frecuencia de los Genes , Genotipo , Haplotipos , Homocigoto , Humanos , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Polimorfismo de Longitud del Fragmento de Restricción , Polimorfismo Conformacional Retorcido-SimpleRESUMEN
This study examined the effect a polymorphism (L162V) in the gene for peroxisome proliferator activated receptor (PPAR) alpha in the development of non-insulin-dependent diabetes mellitus (type 2 DM), obesity and hyperlipidaemia. The frequency of the L162V polymorphism in the PPARalpha gene was determined in 370 morbidly obese patients who underwent gastric banding surgery, 154 patients attending a type 2 DM clinic, 188 patients attending a lipid clinic and 199 healthy blood donors. The overall frequency of the V allele of the L162V polymorphism was 0.06. There were no significant differences in the allele frequency between patients with morbid obesity, hyperlipidaemia, type 2 DM and healthy controls, suggesting that it does not play a major role in the development of these conditions. The polymorphism was associated with a lower body mass index (BMI) in two independently recruited groups of patients with type 2 DM. There was no effect of the polymorphism on subjects without type 2 DM. Thus a polymorphism in PPARalpha protects type 2 DM patients from the overweight which is frequently associated with their condition.
Asunto(s)
Diabetes Mellitus Tipo 2/genética , Diabetes Mellitus/genética , Hiperlipidemias/genética , Obesidad Mórbida/genética , Obesidad , Polimorfismo Genético , Receptores Citoplasmáticos y Nucleares/genética , Factores de Transcripción/genética , Adulto , Anciano , Animales , Glucemia , Índice de Masa Corporal , Diabetes Mellitus/fisiopatología , Diabetes Mellitus Tipo 2/fisiopatología , Femenino , Frecuencia de los Genes , Humanos , Hiperlipidemias/fisiopatología , Lípidos/sangre , Masculino , Persona de Mediana Edad , Obesidad Mórbida/fisiopatologíaRESUMEN
Over the past 10 years, many advances have been made in our understanding of the intravascular metabolism of triglyceride-rich lipoproteins. It is now known that the complex extracellular interactions of triglyceride-rich lipoprotein-associated apolipoprotein E, lipoprotein lipase and hepatic lipase with heparan sulfate proteoglycans and lipoprotein receptors facilitate the hepatocellular uptake of triglyceride-rich lipoproteins. Recent studies have also revealed that the intracellular fate of internalized triglyceride-rich lipoproteins is highly complex. The dissociation of triglyceride-rich lipoprotein components within intracellular endosomal compartments involves the recycling of apolipoprotein E, whereas the remaining lipid core associated with apolipoprotein B is susceptible to lysosomal degradation. Apolipoprotein E recycling is an important newly discovered feature of lipoprotein metabolism, and will be discussed in the context of its intracellular transport mechanisms and cholesterol efflux. Current concepts concerning its potential relevance with regard to lipoprotein metabolism and atherosclerosis will also be discussed.
Asunto(s)
Lipoproteínas/metabolismo , Triglicéridos/metabolismo , Animales , Apolipoproteínas B/metabolismo , Apolipoproteínas C/metabolismo , Apolipoproteínas E/metabolismo , Colesterol/metabolismo , Endosomas/metabolismo , Humanos , Modelos Biológicos , Unión ProteicaRESUMEN
The oxidation hypothesis of atherosclerosis implies that antioxidants are able to inhibit lipoprotein oxidation in the arterial wall and thereby retard atherogenesis. Since most of the animal studies performed have used very high doses of antioxidants, it is to date unknown whether antioxidants are effective antiatherosclerotic agents when given in pharmacological doses. Here we addressed this question using homozygous Watanabe heritable hyperlipidaemic (WHHL) rabbits as an animal model of atherosclerosis. The rabbits were divided into four groups, each consisting of ten animals. They received either a standard diet or a diet containing 4.3 mg ubiquinone-10, or 4.3 mg vitamin E or 15 mg probucol/kg body weight daily. After 12 months, the extent of aortic atherosclerosis was assessed as the intima thickness, media thickness and intima-to-media ratio in 14 cross sections equally distributed over the whole aorta. To evaluate the antioxidant effects of the diet, lipophilic and hydrophilic antioxidants, lipids, fatty acids and plasma oxidizability were measured after 0, 3 and 6 months of feeding. We found that supplementation with probucol significantly decreased aortic intima-to-media ratio compared to controls. The antiatherosclerotic action of probucol was accompanied by its beneficial action on plasma oxidizability and some plasma antioxidants. No decrease in aortic atherosclerosis was measured in ubiquinone-10- and vitamin E-supplemented rabbits, despite the fact that both antioxidants decreased plasma oxidizability and ubiquinone-10 increased the plasma levels of antioxidants. Taken together, these data suggest that pharmacological doses of probucol retard atherogenesis in WHHL rabbits by an antioxidant mechanism, while ubiquinone-10 and vitamin E at these dosages are ineffective in this highly hyperlipidaemic model. The measurement of some oxidation-related parameters in plasma, such as lipophilic antioxidants, polyunsaturated fatty acids and lipoprotein oxidizability, may be useful in assessing the risk of atherogenesis in humans.
Asunto(s)
Antioxidantes/administración & dosificación , Arteriosclerosis/prevención & control , Hiperlipidemias/terapia , Oxidación-Reducción/efectos de los fármacos , Administración Oral , Animales , Anticolesterolemiantes/administración & dosificación , Anticolesterolemiantes/farmacocinética , Antídotos/administración & dosificación , Antídotos/farmacocinética , Antioxidantes/farmacocinética , Aorta/efectos de los fármacos , Aorta/patología , Arteriosclerosis/sangre , Arteriosclerosis/etiología , Arteriosclerosis/patología , Dieta , Relación Dosis-Respuesta a Droga , Ácidos Grasos Insaturados/sangre , Hiperlipidemias/sangre , Hiperlipidemias/complicaciones , Lipoproteínas/sangre , Probucol/administración & dosificación , Probucol/farmacocinética , Conejos , Túnica Íntima/efectos de los fármacos , Túnica Íntima/patología , Ubiquinona/administración & dosificación , Ubiquinona/farmacocinética , Vitamina E/administración & dosificación , Vitamina E/farmacocinéticaRESUMEN
Amyloid-beta (Abeta) peptide, a major constituent of senile plaques and a hallmark of Alzheimer's disease (AD), is normally secreted by neurons and can be found in low concentrations in cerebrospinal fluid (CSF) and plasma, where it is associated with lipoproteins. However, the physiological role of Abeta secretion remains unknown. Here we show that at the concentrations measured in biological fluids (0.1-1.0 nM), Abeta(1-40) strongly inhibits autooxidation of CSF lipoproteins and plasma low density lipoprotein (LDL). At higher concentrations of the peptide its antioxidant action was abolished. Abeta(1-40) also inhibited copper-catalyzed LDL oxidation when added in molar excess of copper, but did not influence oxidation induced by an azo-initiator. Other Abeta peptides also possessed antioxidant activity in the order Abeta(1-40) > Abeta(1-42) > Abeta(25-35), whereas Abeta(35-25) was inactive. These data suggest that Abeta(1-40) may act as a physiological antioxidant in CSF and plasma lipoproteins, functioning by chelating transition metal ions.
Asunto(s)
Péptidos beta-Amiloides/farmacología , Antioxidantes/farmacología , Lipoproteínas/sangre , Lipoproteínas/líquido cefalorraquídeo , Adulto , Enfermedad de Alzheimer , Colesterol/metabolismo , Cobre/química , Cobre/farmacología , Humanos , Peróxido de Hidrógeno/metabolismo , Cinética , Ácido Linoleico/metabolismo , Peroxidación de Lípido/efectos de los fármacos , Lipoproteínas LDL/sangre , Lipoproteínas LDL/metabolismo , Oxidación-Reducción , Fragmentos de Péptidos/farmacologíaRESUMEN
Amyloid-beta (A beta) peptide, a major constituent of senile plaques and a hallmark of Alzheimer's disease (AD), is normally secreted by neurons and can be found in low concentrations in cerebrospinal fluid (CSF) and plasma where it is associated with lipoproteins. However, the physiological role of A beta secretion remains unknown. We measured the resistance to in vitro oxidation of CSF obtained from 20 control subjects and 30 patients with AD, and correlated it with CSF levels of antioxidants, lipids and A beta. We found that the oxidative resistance, expressed as a duration of the oxidation lag-phase, was directly related to CSF levels of A beta 1-40, A beta 1-42 and ascorbate and inversely to levels of fatty acids. These data suggest that, besides ascorbate, A beta is another major physiological antioxidant for CSF lipoproteins.
Asunto(s)
Enfermedad de Alzheimer/líquido cefalorraquídeo , Péptidos beta-Amiloides/líquido cefalorraquídeo , Antioxidantes/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Ácido Ascórbico/líquido cefalorraquídeo , Estudios de Casos y Controles , Humanos , Técnicas In Vitro , Cinética , Lípidos/líquido cefalorraquídeo , Lipoproteínas/líquido cefalorraquídeo , Persona de Mediana Edad , Oxidación-Reducción , Estrés Oxidativo , alfa-Tocoferol/líquido cefalorraquídeoRESUMEN
Oxidative processes are involved in aging as well as the pathogenesis of different degenerative diseases. In the last few years the role of low density lipoprotein oxidation in the development of artherosclerosis and coronary heart disease has become evident. Lipoprotein oxidation in plasma is used as a marker for disease progression. We were interested in the role of lipoprotein oxidation in Alzheimer's disease. For this purpose we developed methods to determine the in vitro oxidizability of cerebrospinal fluid and plasma lipoproteins of Alzheimer patients. In addition we measured the lipophilic and hydrophillic antioxidants, alpha-tocopherol (vitamin E) and ascorbate (vitamin C). Cerebrospinal fluid and plasma lipoprotein oxidation was found to be increased in Alzheimer's patients compared to controls and a corresponding decrease of antioxidant vitamins was found. In a pilot study, in vitro lipoprotein oxidation in cerebrospinal fluid of Alzheimer patients could be delayed by vitamin E and C supplementation. In conclusion these data show that increased lipoprotein oxidation could play an important role in Alzheimer's disease and possibly provide a rationale for the treatment of this disease with antioxidant drugs. The clinical effect of this therapeutical approach remains to be proved in long-term studies.
Asunto(s)
Enfermedad de Alzheimer/fisiopatología , Senescencia Celular/fisiología , Enfermedad de la Arteria Coronaria/fisiopatología , Peroxidación de Lípido/fisiología , Estrés Oxidativo/fisiología , Anciano , Antioxidantes/administración & dosificación , Antioxidantes/metabolismo , Femenino , Humanos , Lipoproteínas/metabolismo , MasculinoRESUMEN
As part of the ApoEurope Project, apolipoprotein E (apo E) common polymorphism and serum concentration were determined in 489 Alzheimer's disease patients and 429 controls. Patients and controls were recruited through nine centres in eight European countries. Age, sex ratios and education levels of both case and control populations were similar, although discrete differences appeared between centres. The prevalence of the epsilon4 allele was higher in Alzheimer's disease than in controls (increased by 140%), while serum apo E concentration was lower by 11.2% (p<0.001). In addition, serum total cholesterol and triglyceride concentrations were lower in Alzheimer's disease (p<0.001), while that of apo Al was not affected. The decrease in serum apo E concentration was not accounted for by the epsilon4 allele, age or gender, suggesting that apo E concentration might represent an additional risk factor for Alzheimer's disease, complementary and independent of the epsilon4 allele. Further analysis will be aimed at determining whether the quantitative link between apo E concentration and Alzheimer's disease occurs through the effect of apo E genotype on lipid parameters or by other mechanisms.
Asunto(s)
Enfermedad de Alzheimer/sangre , Enfermedad de Alzheimer/genética , Apolipoproteínas E/sangre , Apolipoproteínas E/genética , Polimorfismo Genético , Factores de Edad , Anciano , Anciano de 80 o más Años , Alelos , Estudios de Casos y Controles , Educación , Europa (Continente) , Femenino , Frecuencia de los Genes , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Factores SexualesRESUMEN
OBJECTIVE: To determine the role of polymorphisms in the genes for beta3-adrenergic receptor (beta3-AR) and in uncoupling proteins 1 and 2 (UCP-1, UCP-2) in obesity. DESIGN: Association study with three polymorphisms and obesity. SUBJECTS: Two hundred and thirty-six morbidly obese patients who underwent gastric banding surgery, 381 patients from the medical clinic and 198 healthy blood donors. MEASUREMENTS: The frequencies of the W64R in beta3-AR, the 3826A-->G in UCP-1 and the 45bp insertion in the 3 untranslated region of exon 8 in UCP-2 polymorphisms were determined. RESULTS: There were no significant differences in the frequencies of the beta3-AR and UCP-1 polymorphisms between obese (body mass index, BMI > 30 kg/m2) and lean subjects. Lean, but not obese, carriers of the R allele of beta3-AR had a significantly higher BMI. The mean age of obese subjects (excluding diabetics) who were carriers of the G allele of the UCP-1 polymorphism, 36y, was significantly younger than wild-type, 40y (P= 0.007). This effect was not seen in lean subjects. The effect of the G allele on the mean age of obese subjects was more apparent in subjects who were also carriers of the R allele of the beta3-AR polymorphism. The frequency of the ins allele of UCP-2 was significantly higher in obese subjects, 0.31, than in lean, 0.24 (P= 0.002) and carriers of the ins allele had a significantly higher BMI, 38 vs 35 (P= 0.005). There was no association between any of the polymorphisms and type II diabetes. CONCLUSION: In a German population, there was no association between the W64R in beta3-AR or the 3826A-->G in UCP-1 polymorphisms and obesity. However, they act synergistically to accelerate the development of obesity. The 45bp insertion in the 3 untranslated region of exon 8 in UCP-2 polymorphism is associated with obesity.